Table 1.
Baseline characteristics of subjects in the RNAseq development and test sets.
| RNAseq Development set | RNAseq Test Set | Development vs. Test Set P valueB |
|||||
|---|---|---|---|---|---|---|---|
| All (n = 150) |
Asthma (n = 53) |
No Asthma (n = 97) |
All (n = 40) |
Asthma (n = 13) |
No Asthma (n = 27) |
||
| Age: years | 26.9 (5.4) | 25.7 (2.0) | 27.6 (6.5) | 26.2 (5.1) | 25.3 (2.1) | 26.6 (6.1) | 0.47 |
| Sex: female | 89 (59.3%) | 24 (45.3%) | 65 (67.0%) | 21 (52.5%) | 2 (15.3%) | 19 (70.4%) | 0.40 |
| Race | 0.60 | ||||||
| Caucasian | 116 (77.3%) | 21 (40.4%) | 96 (99.0%) | 32 (80.0%) | 5 (38.5%) | 27 (100.0%) | |
| African American |
24 (16.0%) | 23 (43.4%) | 1 (1.0%) | 5 (12.5%) | 5 (38.5%) | 0 (0.0%) | |
| Latino | 5 (3.3%) | 5 (9.4%) | 0 (0.0%) | 3 (7.5%) | 3 (23.1%) | 0 (0.0%) | |
| Other | 5 (3.3%) | 4 (7.5%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
| FEV1A: % predicted |
94.7 (10.0) | 94.6% (10.9) | 94.8 (9.7) | 94.5 (11.4) | 94.4 (12.0) | 94.6 (11.3) | 0.90 |
| FEV1/FVCA: % | 82.5 (6.4) | 81.5 (6.7) | 83.1 (6.3) | 82.7 (5.5) | 84.8 (4.4) | 81.6 (5.8) | 0.91 |
| Bronchodilator response: % | 5.6 (6.0) | 8.7 (6.4) | 3.9 (5.1) | 4.5 (5.4) | 7.0 (6.1) | 3.3 (4.7) | 0.29 |
| Age asthma onset: years | 3.2 (2.7) | n/a | 3.4 (2.0) | 0.78 | |||
| Allergic rhinitis | 60 (40.0%) | 29 (54.7%) | 31 (32.0%) | 7 (17.5%) | 7 (53.8%) | 0 (0.0%) | 0.009 |
| Nasal steroids | 14 (9.3%) | 9 (17.0%) | 5 (5.2%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0.07 |
| Smoking | 7 (4.7%) | 1 (1.9%) | 6 (6.2%) | 1 (2.5%) | 0 (0.0%) | 1 (3.7%) | 1.0 |
Mean (SD) or Number (%) provided.
Apre-bronchodilator measures. FEV1 = forced expiratory flow volume in 1 second, FVC = forced vital capacity.
BFisher’s Exact test for categorical variables and t-test for continuous variable.